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The aim of this study was to evaluate the epidemiology, clinical and labor-
atory characteristics of canine lymphomas as well as some aspects of treatment 
outcomes. The study was conducted on Boxer dogs with lymphoma diagnosed by 
cytology and immunocytochemistry (CD3 and CD79 alpha). During the study pe-
riod, lymphoma was diagnosed in 63 Boxers; 86.8% were T-cell (based on the 
Kiel classification: small clear cell lymphoma, pleomorphic small cell lymphoma, 
pleomorphic mixed T-cell lymphoma, pleomorphic large T-cell lymphoma, lym-
phoblastic lymphoma/acute lymphoblastic leukaemia) and 13.2% were B-cell 
lymphomas (according to the Kiel classification: B-cell chronic lymphocytic leu-
kaemia, centroblastic/centroblastic polymorphic lymphoma). Overall survival 
(OS) was significantly longer in dogs with low-grade than with high-grade lym-
phoma (median OS of 6.8 and 4.7 months, respectively; P = 0.024). OS was not 
influenced by WHO clinical stage, WHO clinical substage, presence of spleno-
megaly, early administration of glucocorticoids or the time from the first presenta-
tion to the beginning of chemotherapy. There are no significant differences in 
clinical and laboratory parameters between low-grade and high-grade lymphomas. 
Boxer dogs are predisposed to T-cell lymphoma, with a predominance of high-
grade tumour, especially pleomorphic, mixed small and large T-cell subtype. It is 
possible that Boxer dogs may respond less favourably to chemotherapy than pa-
tients of other breeds.  
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Breed predilections for specific lymphoma subtypes are well characterised 
in the veterinary literature; however, descriptions of larger groups of affected 
dogs of one breed are uncommon (Lurie et al., 2004; Lurie et al., 2008; Sutter 
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and Ostrander, 2004; Modiano et al., 2005; Dobson, 2013). Even though the ae-
tiology of most neoplasms appears to be multifactorial, the high level of genetic 
homogeneity within dog breeds is presumably responsible, to some extent, for 
predisposition to specific tumours (Sutter and Ostrander, 2004; Modiano et al., 
2005; Dobson, 2013). The prevalence of T-cell lymphoproliferative disease is the 
highest in Spitz breeds (Akita, Basenji, Siberian Husky, Alaskan Malamute, Chi-
nese Shar-Pei and wolves) and in the Shih Tzu group (Shih Tzu, Lhasa Apso, 
and other Asian ‘lap’ dogs; Modiano et al., 2005). Boxers show an increased risk 
of developing T-cell tumours, since as many as 55 to 85% of Boxers with lym-
phoma have tumours of T-cell immunophenotype (Lurie et al., 2004; Modiano et 
al., 2005; Lurie et al., 2008; Pastor et al., 2009; Jankowska et al., 2015). The lim-
ited genetic diversity within dog breeds facilitates genetic linkage or association 
studies on relatively small populations as compared to humans (Modiano et al., 
2005; Cadieu and Ostrander, 2007; Olson, 2007; Shearin and Ostrander, 2010). 
The studies regarding predilection for different types of tumours in the canine 
population may be beneficial for elucidating the aetiology and pathogenesis of 
human neoplasms. 
This strong breed association with different subtypes of lymphoma may at 
least partly explain differences in clinical presentation, response to chemotherapy 
and survival time in certain dog breeds (Garret et al., 2002). Dogs with some 
subtypes of T-cell lymphoma are at a significantly higher risk of poorer response 
to therapy as well as relapse and early death following therapy compared to those 
with B-cell lymphoma (Ruslander et al., 1997; Ponce et al., 2003). The aim of 
this study was to evaluate the epidemiological, clinical and laboratory character-
istics of lymphoma-affected Boxer dogs, including some aspects of treatment 
outcomes. 
 
Materials and methods 
Study population and collection of cases 
The study was conducted on canine patients in 2009–2015. Lymphoma 
was diagnosed in 63 Boxer dogs, but full data were available only for 29 of 
them. The rest of the dogs without full data available (n = 34) were included in 
the epidemiological and cytological analyses. In the study period, all cases diag-
nosed cytologically as canine lymphomas were provisionally collected and data 
on age, breed, and sex were recorded. In every Boxer dog with a diagnosis of 
lymphoma, additionally the results of full clinical examination, abdominal ultra-
sonography, complete blood count and biochemical parameters including total 
calcium, albumins, total protein, alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase (AP), total bilirubin, creatinine and 
urea were measured in laboratories with systems of daily internal and periodic 
external quality control (‘VetLab’ and ‘LabWet’ in Warsaw, Poland; using Dia-
226 JANKOWSKA et al. 
Acta Veterinaria Hungarica 67, 2019 
tron Abacus Vet5, Cormay Mythic 18, MetroLab 2300 PLUS, Siemens RapiD-
Chem 744, Siemens Immulite 2000 XPi, Siemens DPC Immulite One, ERBA 
640 XL and Mindray BS-800 devices). In addition, information was collected 
about the treatment scheme and its results, if available. Smears for cytological 
examination were obtained by fine-needle aspiration or non-aspiration biopsy of 
enlarged lymph nodes (in cases of systemic lymphadenomegaly samples were 
collected from at least two enlarged lymph nodes and at least three samples from 
each examined lymph node were taken) and/or from abnormal masses located on 
the skin (in two cases) and in body cavities (mediastinal tumours – 5 dogs and 
abdominal cavity tumours – one patient), bone marrow, if leukocytosis was ob-
served in peripheral blood smears (one each from group with T-cell and B-cell 
lymphoma) and fluids from serosal cavities (sediment fluids from the pleural 
cavity were taken from two patients). Samples were also collected from the spleen 
or liver if splenomegaly or hepatomegaly were detected (in a total of 6 and 25 
cases, respectively). If necessary, the sampling was performed in local anaesthe-
sia or sedation/narcosis using topical lignocaine (Lignocainum hydrochloricum 
2%; Warszawskie Zakłady Farmaceutyczne Polfa, Poland) and, for general an-
aesthesia, butorphanol (Butomidor 10 mg/ml; Richter Pharma AG, Austria), 
dexmedetomidine (Dexdomitor 0.5 mg/ml; Orion Pharma, Finland), ketamine 
(Bioketan 100 mg/ml; Vetoquinol Biowet Puławy, Poland) or propofol (Propofol- 
Lipuro 10 mg/ml; B. Braun, Germany). Finally, all Boxer dogs, in which the cy-
tomorphological diagnosis of lymphoma was made and its subtype was recog-
nised unequivocally twice by the same clinical cytologist (the period between 
first examination and re-examination of the slides by the cytologist was between 
1 and 2 months), were enrolled in the study. Moreover, to confirm the diagnosis 
of lymphoma subtype, immunocytochemistry was performed if a sufficient num-
ber of slides were available. For 29 cases the history of treatment was document-
ed: in 9 Boxer dogs with low-grade lymphoma and 20 with high-grade lympho-
ma. The procedure was standardised to 5 groups: Group I: without treatment (n = 
8; 2 dogs with low-grade and 6 with high-grade lymphomas); Group II: only 
prednisolone (n = 9; 4 cases with low-grade and 5 with high-grade lymphoma); 
Group III: COP-based (n = 2; only low-grade lymphomas); Group IV: CHOP-
based (n = 9); Group V: cyclophosphamide orally (n = 1). In 9 patients receiving 
treatment according to the CHOP-based protocol changes were introduced con-
cerning the exclusion of Asparaginase and/or Lomustine – only the base of 
CHOP: n = 3; CHOP with Asparaginase: n = 1; CHOP with Lomustine: n = 3; 
CHOP with Asparaginase and Lomustine: n = 2. The modifications resulted from 
the course of the disease and the possibilities of dog owners. The administration 
of glucocorticoids before the start of chemotherapy was reported by 34% of dog 
owners (n = 10; 7 of high-grade lymphoma). The therapy lasted 38 days on aver-
age. 
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Slide preparation and immunocytochemistry 
For routine examination at least 3 smears of aspirates were dried, fixed in 
70% methanol, stained with Giemsa solution and examined by light microscopy. 
For immunocytochemical assays, smears from each dog were dried, fixed in ace-
tone at 4 °C for 5–10 min, and stained immediately or stored at –20 °C. Immuno-
cytochemical staining was performed according to Caniatti et al. (1996) and 
Sapierzyński (2010) using commercially available antibodies (Dako®, Glostrup, 
Denmark) for the pan T-lymphocyte marker CD3 (Polyclonal Rabbit Anti-
Human) and B-cell antigen receptor complex CD79α (Monoclonal Mouse Anti-
Human). Two smears from the same case were stained using both antibodies. 
The expression intensity of the examined CD antigens in cytological preparations 
was determined in a light microscope and the result was considered positive if at 
least 80% of the lymphoid cells showed a strong cytoplasmic reaction (i.e., T cell 
immunophenotype was established if at least 80% of the lymphocytes were CD3 
immunopositive, and B cell immunophenotype was established if at least 80% of 
the lymphocytes were CD79α immunopositive). The entire slide was searched, 
and immunopositive cells were calculated among 1000 cells using an Olympus 
BX41 microscope coupled to a computer equipped with CellA® analysis system 
(images of microscopic fields abundant in well preserved cells were captured and 
formatted as .TIFF files, and the immunoexpression of CD3 and CD79α was cal-
culated). Negative controls were processed in the same manner, using buffer so-
lution instead of primary antibodies. The positive controls for CD3 and CD79α 
were cellular samples collected from impression smears of canine hyperplastic 
lymph nodes. The results of immunocytochemistry were interpreted blindly 
without knowledge of the lymphoma subtype recognised in routine cytology. 
Criteria of lymphoma diagnosis 
The type and subtype of the tumours were determined on the basis of the 
updated Kiel cytological classification adopted for dogs as previously described 
(Fournel-Fleury et al., 1997; Fournel-Fleury et al., 2002; Ponce et al., 2010) and 
supported by the results of immunocytochemistry. For the cytopathological diag-
nosis the following features were considered: size and shape of cells, volume and 
intensity of cytoplasm staining, size and shape of nuclei, the position of nucleus 
in a cell; size, distinctness, number and positioning of nucleoli, and appearance 
of nuclear chromatin. Additionally, the mitotic rate (MR) was established in cy-
tological specimens according to Fournel-Fleury et al. (1997). Based on the mi-
croscopic observation, the diagnosed lymphomas were classified as low-grade (at 
least 90% of small cells and low or medium MR) and high-grade lymphomas (at 
least 80% of medium and/or large cells and high MR) and, more precisely, as cy-
tological subtypes according to the updated Kiel classification. 
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Influence of neutering on lymphoma occurrence 
A case-control study was carried out. Veterinary records from one clinic 
were browsed for Boxers with and without lymphoma (henceforth referred to as 
diseased and control group, respectively). Then, their age either at the moment of 
lymphoma diagnosis (diseased group) or at the moment when they last showed 
up at the clinic (control group) was recorded, and neutering status was deter-
mined by reviewing direct entries in the database, including the description of 
abdominal surgeries and/or ultrasonographies performed. Then, a control group 
was built by frequency matching of Boxers without lymphoma at the same age 
range (Thrusfield, 2007), as the link between age and lymphoma is well known 
(Grüntzig et al., 2016; Villamil et al., 2009). 
Statistical analysis 
Numerical variables were presented as a median, interquartile range (IQR) 
and range, and compared between groups with a Mann–Whitney U test or a 
Kruskal–Wallis H test. Categorical variables were given as a count and percent-
age, and compared between groups with a Pearson’s chi-square test or Fisher’s 
exact test, depending on the expected count of observations in cells of the con-
tingency table. The relationship between neutering and lymphoma was investi-
gated using a Cochran–Mantel–Haenszel test controlling for sex as a potential 
confounder, since sex appears to be associated with the occurrence of lymphoma 
(Villamil et al., 2009; Grüntzig et al., 2016). Crude odds ratios (OR) were calcu-
lated separately for males and females from partial two-by-two contingency ta-
bles and the homogeneity of OR was verified with a Breslow–Day test in Taro-
ne’s modification. If the homogeneity of OR proved insignificant, the common 
OR (ORMH) were calculated with a Mantel–Haenszel procedure. A 95% confi-
dence interval (CI 95%) for OR was always reported, and CI 95% for proportion 
was calculated using the Wilson score method. The overall survival time (OS) of 
Boxers with lymphoma was analysed using a Kaplan–Meyer plot. As no censor-
ing was included (all dogs died of lymphoma), OS were compared between 
groups using a Gehan–Wilcoxon test (2 groups) or generalised Mantel–Cox test 
(3 groups). The significance level (α) was set at 0.05 and all statistical tests were 
two-sided. Analysis was performed in Statistica 12 (StatSoft Inc., Tulsa, OK) 
and IBM SPSS Statistics 24. 
 
Results 
Epidemiology 
During the study period lymphoma was diagnosed in 353 dogs, including 
63 Boxers (17.9% of all dogs) that met the inclusion criteria. There were no dis-
crepancies between diagnoses of lymphoma and its subtype during the first ex-
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amination and when re-examining the slides, as well as the diagnosis of the sub-
type of lymphoma and the immunophenotype established by immunocytochem-
istry. There were 23 males (36.5%) and 40 females (63.5%) among the Boxers. 
Their age ranged from 3 to 14 years with a median of 8 years (IQR from 7 to 10 
years; a frequency chart for the age of male and female Boxer dogs is presented 
in Fig. 1) and did not differ between the sexes (P = 0.789). Age also did not dif-
fer between neutered (n = 4) and intact (n = 19) males (P = 0.806), nor between 
spayed (n = 22) and intact (n = 18) females (P = 0.320). 
 
Fig. 1. The number of male and female dogs of different age 
Data on neutering 
Data on neutering were available for 63 Boxers with lymphoma and 387 
Boxers without lymphoma. As the age of Boxers with lymphoma ranged from 3 
to 14 years, a control group was built by matching Boxers without lymphoma at 
the same age range. This resulted in excluding 64 Boxers younger than 3 years 
(31 males, 33 females) and 4 Boxers older than 14 years (1 male, 3 females). 
Eventually, the control group counted 319 Boxers without lymphoma, 145 males 
(45.5%) and 174 females (54.5%), at the median age of 9 years (IQR from 6 to 
11 years), which did not differ from the age of diseased Boxers (P = 0.586). The 
proportion of castrated individuals in the lymphoma and control group stratified 
by sex is shown in Fig. 2. Case-to-control ratio was 6.3 in males and 4.4 in fe-
males. Female boxers were neutered significantly more often (85 of all 214 fe-
males; 39.7%) than males (26 of all 168 males; 15.5%) (P < 0.001). This pattern 
was identical in both the lymphoma and the control groups: in the lymphoma 
group of Boxers only 4 of 23 males (17.4%; CI 95%: 7.0%, 37.1%) and as many 
as 22 of 40 females (55.0%; CI 95%: 39.8%, 69.3%) were neutered (P = 0.004); 
in the control group, 22 of 145 males (15.2%; CI 95%: 10.2%, 21.9%) and 63 of 
174 females (36.2%; CI 95%: 29.4%, 43.6%) were neutered (P < 0.001). Given 
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the expected OR of 2, exposure in controls of 15% in males and 35% in females, 
case-to-control ratio of 6.3 in males and 4.4 in females, and α = 0.05, the power 
of this case-control study was only 29% in males and 51% in females. For males 
the OR of neutering was 1.18 (0.37, 3.79; P = 0.785). For females the OR of 
spaying was 2.15 (CI 95%: 1.07, 4.32; P = 0.029). ORs were homogeneous (P = 
0.383) and ORMH was 1.84 (CI 95%: 1.02, 3.31; P = 0.042). 
 
Fig. 2. Proportion of castrated individuals (with a CI of 95%) in the lymphoma and the control 
group stratified by sex 
Cytology 
The immunophenotype was known for 53 (84.1%) of 63 Boxers with lym-
phoma; 46 (86.8%) were T-cell lymphomas and 7 (13.2%) were B-cell lympho-
mas. Thirty-four (64.2%) were high-grade lymphomas and 19 (35.8%) were low-
grade or indolent lymphomas. According to the Kiel classification the most 
common subtypes included the pleomorphic, mixed small and large lymphoma 
(Pleosl; n = 21; 40%), clear cell lymphoma (CC; n = 16; 30%), centroblastic ple-
omorphic B-cell lymphoma (Cbl; n = 6; 11%), plasmacytoid high-grade T-cell 
lymphoma (n = 3; 6%) and other subtypes (13%), including acute lymphoblastic 
T-cell leukaemia/lymphoma, pleomorphic large cell lymphoma (PleoL), pleo-
morphic small cell lymphoma (PleoS), prolymphocytic T-cell lymphoma and 
small lymphocytic/chronic lymphocytic B-cell lymphoma/leukaemia – less than 
3 cases of each subtype. According to the WHO classification, among all T-cell 
lymphomas, 44 (96% of T-cell lymphomas) were presumably classified as pe-
ripheral T-cell lymphomas and 2 (4% of T-cell lymphomas) as precursor T-cell 
lymphomas. Among all B-cell lymphomas, 6 were presumably classified as dif-
fuse large B-cell lymphomas and one as small cell B lymphoma. Table 1 summa-
rises the cytological diagnoses of 53 Boxer dogs with lymphoma of confirmed 
immunophenotype. 
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Table 1 
Summarised cytological diagnoses for 53 Boxer dogs with lymphomas immunophenotyped by 
immunocytochemistry 
Types Grades WHO classification Kiel classification Number  of cases 
T-cell 
High-grade 
peripheral T-cell 
lymphoma 
pleomorphic, mixed small and  
large lymphoma 
 
21 
plasmacytoid high-grade T-cell  
lymphoma 
 
3 
pleomorphic large cell lymphoma 1 
prolymphocytic T-cell lymphoma 1 
precursor T-cell 
lymphoma 
acute lymphoblastic T-cell leukaemia/ 
lymphoma 
 
2 
Low-grade peripheral T-cell lymphoma 
clear cell lymphoma 16 
pleomorphic small cell lymphoma 2 
B-cell 
High-grade diffuse large B-cell lymphoma 
centroblastic pleomorphic B-cell  
lymphoma 
 
6 
Low-grade small cell B lym-phoma 
small lymphocytic/chronic lymphocytic 
B-cell lymphoma/leukaemia 
 
1 
 
Boxers with high-grade lymphomas were significantly younger than those 
with low-grade lymphoma (Fig. 3; P = 0.036). All Boxers younger than 6 years 
of age had a high-grade lymphoma. Males and females did not differ with respect 
to the occurrence of high-grade lymphoma (P = 0.336), nor by lymphoma sub-
type (pleomorphic, mixed, small and large lymphoma; clear cell lymphoma and 
centroblastic lymphoma; P = 0.580). 
Clinical findings 
Detailed clinical examination was performed in 29 Boxers with T-cell 
lymphoma; only 5 of these dogs (17%) did not have clinical signs (substage a), 
24 (83%) dogs manifested clinical signs (substage b). According to the WHO 
clinical staging, most of the Boxers had clinical stage IV (14 cases, 48%; in-
volvement of spleen and/or liver) or III (13 cases, 44%); only one dog had clini-
cal stage I and one dog had clinical stage V (4% of cases; involvement of periph-
eral blood or/and bone marrow). There were no significant differences in WHO 
clinical stage Between boxers with low-grade and high-grade lymphomas (P = 
0.322), nor were there any differences in the occurrence of various clinical signs 
(observed by owners or detected at the moment of first presentation) between 
low-grade and high-grade lymphomas (detailed data not shown). 
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Fig. 3. Comparison of median age of Boxer dogs with high-grade T-cell lymphoma and low-grade 
T-cell lymphoma. IQR stands for the interquartile range (50% central values) 
Table 2 
Summarised data on alterations in laboratory parameters in Boxer dogs with lymphoma 
Laboratory changes Number (%) of cases 
Leukocytosis (WBC > 12.0 G/L) 11 (42%) 
Anaemia – haematocrit (HCT < 37%) 3 (12%) 
Anaemia – haemoglobin (HGB < 7.45 mmol/L) 2 (8%) 
Anaemia – red blood cell count (RBC < 5.5 T/L) 2 (8%) 
Thrombocytopenia (PLT < 200 G/L) 11 (42%) 
Hypercalcaemia (Ca > 11.5 mg/dL) 9 (36%) 
Hypoalbuminaemia (ALB < 33 g/L) 7 (33%) 
Hyperproteinaemia (TP > 55 g/L) 3 (12%) 
Hepatic parameters – alanine aminotransferase (ALT > 50 U/L) 20 (80%) 
Hepatic parameters – aspartate aminotransferase (AST > 37 U/L) 7 (50%) 
Hepatic parameters – alkaline phosphatase (AP > 155 U/L) 4 (22%) 
Hepatic parameters – total bilirubin (TB > 0.9 mg/dL) 3 (20%) 
Renal parameters – creatinine ( CREA > 1.7 mg/dL) 4 (16%) 
Renal parameters – urea (urea > 45 mg/dL) 6 (24%) 
Haematology and biochemistry 
There was no association between lymphoma grade and the results of 
blood analysis, except for total protein concentration, which was significantly 
lower in Boxers with high-grade lymphoma (P = 0.031). The alterations in labor-
atory parameters are summarised in Table 2. The leukaemic phase occurred in 
only one case of high-grade lymphoma (lymphoblastic lymphoma). In the ma-
chine marking of blood 109.8 G/L leukocytes were determined, of which 75% 
were regarded as neoplastic lymphocytes. Severe leukocytosis, lymphocytosis 
and neutropenia were observed in the blood smear, with numerous blastic cells. 
High-grade lymphoma 
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These were large and medium-sized cells. The size of large cells was 2 to 2.5 
times larger than the diameter of the red blood cells (RBCs), and the diameter of 
the medium-sized cells was 1.5 to 1.9 times larger than that of the RBCs. Their 
nuclei were large, round or with irregular margins. The chromatin pattern was 
stippled, coarse and the cells had multiple nucleoli. 
Survival 
Treatment and/or follow up were analysed for 28 Boxers with T-cell lym-
phoma (8 dogs with low-grade clear cell lymphoma and 20 dogs with high-grade 
lymphoma). All dogs died of lymphoma, so no censoring was included in the 
survival analysis. OS was significantly longer in dogs with low-grade than with 
high-grade lymphoma – median OS of 6.8 (IQR from 5.1 to 11.6) months and 
4.7 (IQR from 2.0 to 6.0) months, respectively (P = 0.024; Fig. 4). OS was not 
influenced by WHO clinical stage (P = 0.805), WHO clinical substage (P = 
0.719), presence of splenomegaly (P = 0.864), therapy regimen, i.e. chemothera-
py vs. glucocorticosteroids vs. no treatment (P = 0.365 when dogs with low-
grade and high-grade lymphoma were analysed together or P = 0.216 when only 
dogs with high-grade lymphoma were included; Fig. 5), early administration of 
glucocorticoids (P = 0.445) or the time from the first presentation to the begin-
ning of chemotherapy (P = 0.147). The median OS for 11 Boxer dogs with high-
grade lymphoma without chemotherapy was 2.5 (IQR from 1.5 to 4.8) months 
and was shorter than in 9 Boxer dogs treated with chemotherapy, whose median 
OS was 4.9 (IQR from 3.5 to 7.1) months, but this difference was not statistically 
significant (P = 0.095). 
 
Fig. 4. Kaplan–Meier survival curves in Boxer dogs with low-grade (n = 8; median OS = 6.8 months) 
and high-grade lymphomas (n = 20; median OS = 4.7 months) 
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Fig. 5. Kaplan–Meier survival curves in Boxer dogs treated with chemotherapy (n = 12;  
median OS = 5.1 months), treated with glucocorticosteroids (n = 8; median OS = 4.3 months)  
and not treated at all (n = 8; median OS = 3 months). GCS = glucocorticoids 
 
Discussion 
Boxers are a dog breed with a well-known predisposition to lymphoma 
(Edwards et al., 2004; Jankowska et al., 2015). In American, French, British, and 
Polish studies, Boxers accounted for 4–13% of dogs with lymphoma; moreover, 
Boxers are at a higher risk of T-cell lymphoma tumour development (Lurie et al., 
2004; Modiano et al., 2005; Lurie et al., 2008; Pastor et al., 2009; Rebhun et al., 
2010; Avery et al., 2014; Jankowska et al., 2015; Fontaine et al., 2017; Wilson-
Robles et al., 2017). Our study also shows that neutered Boxers are roughly 
twice more likely to develop lymphoma; however, this applies only to females. 
Some recently published studies have also found that castration increases the risk 
of lymphoma in dogs, even though they draw conflicting conclusions regarding 
the sex group which appears to be predisposed to lymphoma by castration. This 
sex group are males according to de la Riva et al. (2013), females in our study or 
both males and females according to Zink et al. (2014). Another study showed 
that neutered males were in fact at a lower risk of lymphoma development than 
spayed females (Villamil et al., 2009). Given the low power of our analysis (be-
ing a direct consequence of small sample size), our result for males may simply 
be false negative and should be treated with caution. Therefore, our study ap-
pears to add to the general hypothesis that gonadectomised dogs are at a higher 
risk of lymphoma. Steroid sex hormones have been shown to modulate the func-
tion of the immune system (Muñoz-Cruz et al., 2011) and their lack may reduce 
the ability of the immune system to track and eliminate cells undergoing neo-
plastic transformation (Engelmann et al., 2011). However, experimental confir-
mation of this mechanism in dogs is still needed. 
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Lymphomas were recognised in Boxers of all ages. In the present study 
high-grade tumours were diagnosed in younger dogs while low-grade or indolent 
tumours in older dogs, which is similar to what was shown in a general popula-
tion of dogs with T-cell lymphoma (Jankowska et al., 2015). Moreover, only 
high-grade tumours were recognised in dogs younger than 6 years. 
Previous reports have suggested that lymphoma in Boxer dogs is a relatively 
homogeneous disease (Lurie et al., 2004; Lurie et al., 2008). Based on the WHO 
classification criteria, Lurie et al. (2008) suggested that Boxers could be predis-
posed to lymphoblastic lymphoma (as many as three fourths of all lymphoma cases 
occur in this breed). This is at odds with the present study, where lymphoblastic T-
cell tumours were recognised less often (only 4.3% of T-cell lymphomas). Moreo-
ver, in other published studies the percentage of lymphoblastic lymphomas classi-
fied by the Kiel system and one study based on the NCIWF (National Cancer Insti-
tute Working Formulation) in Boxer dogs were closer to our results and comprised 
12.5% and 24–30% of the cases in a general population of dogs with T-cell lym-
phomas, respectively (Fournel-Fleury et al., 2002; Ponce et al., 2003). Although 
there is no clear evidence for the predisposition of Boxers to any specific lympho-
ma subtype, Pastor et al. (2009) and Avery et al. (2014) have suggested that dogs 
of this breed can be predisposed to pleomorphic, mixed small and large T-cell tu-
mour – this subtype was also most commonly observed in our study. However, this 
subtype was rare in a group of Boxer dogs with lymphomas (only 9% of T-cell 
lymphomas) analysed by Lurie et al. (2008). Regardless of the classification 
scheme and the cytomorphologic subtype, among all lymphomas diagnosed in 
Boxer dogs, high-grade tumours are recognised more often than low-grade lym-
phomas (Fournel-Fleury et al., 2002; Lurie et al., 2008, Sapierzyński, 2010). Box-
ers were over-represented in a group of dogs with high-grade T-cell lymphomas 
but were absent in a group of animals with indolent/low-grade T-zone lymphomas 
(de la Riva et al., 2013; Mealey et al., 2003). Interestingly, a significant number of 
Boxers with lymphoma in the present study had clear cell morphology (TZL, T-
zone lymphoma according to the WHO classification) and low proliferative activi-
ty; this is in contrast to a study conducted by Lurie et al. (2008) and Seelig et al. 
(2014) where no cases of CC/T zone lymphomas were diagnosed in Boxer dogs. 
Like in a general population of dogs with lymphoma, a multicentric form 
was most often found in Boxers enrolled in our study. Regardless of tumour lo-
cation and clinical stage of the disease, generally non-specific signs predominat-
ed, commonly with polyuria and polydipsia (54% of all Boxers, including all of 
the 7 patients with hypercalcaemia). Virtually all dogs were in clinical stage III 
or IV according to the WHO classification, and most of them were in clinical 
substage b concerning the occurrence of disease signs, regardless of malignancy 
grade or cytological subtype; however, significant enlargement of the lymph 
nodes was observed only in patients with high-grade lymphoma. The administra-
tion of glucocorticoids for at least a few weeks before the start of chemotherapy 
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could be responsible for the low number of Boxers with marked lymphadeno-
megaly. 
Serious haematological abnormalities were not common in Boxers with 
lymphoma in the present study, apart from mild leukocytosis and mild thrombo-
cytopenia observed in nearly half of the patients, as well as anaemia that was 
noted only in dogs with high-grade tumours. Neoplastic lymphocytosis of mild 
intensity was reported as a common haematological finding in dogs with low-
grade T-zone lymphoma (clear cell lymphoma); however, bone marrow in-
volvement does not seem to be common in such cases (Seelig et al., 2014). Total 
protein concentration was the only biochemical abnormality with significant dif-
ferences among low-grade and high-grade tumours, with lower values in the lat-
ter lymphoma subtype. Recently a decreased concentration of serum albumin has 
been found to be related to reduced overall survival and length of remission in 
dogs with lymphoma (Fontaine et al., 2017). 
Treatment and/or follow-up were analysed for 29 Boxers with T-cell lym-
phoma (9 dogs with low-grade clear cell lymphoma and 20 dogs with high-grade 
lymphomas). As could be expected, the OS differed between dogs with low-
grade and high-grade T-cell lymphoma. In some cases in the present study pred-
nisone therapy was often the only treatment option; it is well known that an im-
portant disadvantage of prednisone treatment is the induction of chemoresistance 
(Mealey et al., 2003; Schmidt et al., 2004; Gavazza et al., 2009). However, our 
results did not show a significant effect of prior administration of glucocorticoids 
on the outcome of treatment with chemotherapy. Median survival time for these 
patients was 144 days, i.e. 4.8 months. On the other hand, in Boxers with high-
grade T-cell lymphomas in the present study, there was little evidence that treat-
ment solely with prednisone was superior to no treatment at all, which corrobo-
rates previous observations (Valli et al., 2013). 
In the present study the exact treatment protocol slightly varied depending 
on the clinical course, but the schedule was generally based on CHOP. We be-
lieve that the lack of significant differences in median OS in dogs with high-
grade tumours treated and not treated with chemotherapy could be, at least par-
tially, explained by the small number of patients in the particular groups. How-
ever, it seems that the possibility that high-grade lymphomas in Boxer dogs are 
clinically more aggressive than in other dog breeds should be considered, so ad-
ditional studies including larger groups of Boxer dogs with high-grade T-cell 
lymphoma are warranted. Our results on the dogs’ survival are comparable to the 
findings of Lurie et al. (2008), where all Boxers presented with advanced disease 
had a median OS of 150 days (the median OS for animals with T-cell tumours 
was 109 days). Among dogs of all breeds with intermediate or high-grade T-cell 
lymphomas (lymphoblastic or peripheral T-cell subtypes) from two other studies, 
the median OS for dogs treated with a CHOP-based protocol was 237 and 235 
days, respectively (Rebhun et al., 2010; Avery et al., 2014). In a study published 
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by Ponce et al. (2003), the median OS for pleomorphic mixed T-cell and lym-
phoblastic lymphomas was 14 and 9 months, respectively. Our findings and the 
results of Lurie et al. (2008) may suggest that Boxer dogs may respond less fa-
vourably to chemotherapy than patients of other breeds in which outcomes can 
be longer (Rebhun et al., 2010; Avery et al., 2014). On the other hand, in a study 
reported by Valli et al. (2013), the median OS for dogs with high-grade T-cell 
lymphomas was 162 days. However, in this study lymphomas were divided into 
groups according to the degree of malignancy (high grade, intermediate grade 
and low grade). The four most common breeds of large dogs (75.6% of cases) in 
descending order were Golden Retrievers, Labrador Retrievers, crossbreed dogs 
and Boxers, so the number of Boxers could influence the outcome of treatment. 
Among all dogs with various subtypes of lymphoma, animals with low-
grade T-cell (T-zone) tumours have the longest median OS (Ponce et al., 2003; 
Valli et al., 2006; Flood-Knapik et al., 2012; Frantz et al., 2013; Valli et al., 
2013). Similarly, OS was the longest in Boxers with clear cell lymphoma (T-
zone lymphoma) in the present study; however, the median OS was not as long 
as in the studies mentioned above (from 21 to 33.5 months vs. 6.8 months in our 
study). Moreover, there was a significant difference in OS between dogs receiv-
ing multi-drug chemotherapy when compared to patients receiving solely predni-
sone, and dogs without treatment in the study of Valli et al. (2006). In another 
study the outcomes in dogs with T-zone lymphoma were longest in patients 
treated without an aggressive chemotherapy schedule (Flood-Knapik et al., 2012). 
In our study the longest survival was achieved in dogs with CC lymphoma with-
out treatment (only 2 dogs, survival time of 1104 and 1802 days). Another three 
Boxers with low-grade clear cell lymphoma had stage III disease, but they had 
clinical signs (substage IIIb), so chemotherapy with multi-agent protocol was in-
troduced. Unfortunately, the OS was relatively short in these cases (median of 
204 days) and similar to the median OS for patients treated with prednisolone 
alone. Dogs with T-zone/CC lymphoma in the present study were probably diag-
nosed during later stages of the disease, as clinical signs associated with lym-
phoma spread were rarely present. Therefore, it should be taken into account that 
the diagnosis was made in the late stage of the disease, hence OS were shorter 
than expected. According to Aresu et al. (2013), the prognosis of advanced indo-
lent lymphoma does not appear to be appreciably different from that of high-
grade tumours. 
The main disadvantage of our study is the relatively small group of Boxers 
with complete clinical data and the heterogeneous chemotherapy schedules that 
were used. The Boxer dogs included in the analysis of treatment were collected 
only from a referral centre, and commonly were referred by general practitioners, 
thus most of them had an advanced form of the disease (83% of patients were in 
substage B). So, it is possible that differences between OS of Boxers in the pre-
sent study and those presented by other authors (Ponce et al., 2003; Rebhun et 
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al., 2010; Avery et al., 2014) may result from the small number of patients with a 
given lymphoma chemotherapy schedule and disease in the advanced stage. The 
second limitation of the study is the lack of histopathological confirmation of 
lymphoma diagnosis. However, many authors have recommended cytology as an 
adequate method for canine lymphoma diagnosis, especially when supported by 
additional tests that allow for immunophenotype confirmation of neoplastic cells 
(immunocytochemistry and/or flow cytometry). Recently, in at least three studies 
focused on canine lymphomas, cytological diagnosis has been one of the inclu-
sion criteria (Brown et al., 2017; Fontaine et al., 2017; Wilson-Robles et al., 2017). 
Fortunately, the cytological picture of most common subtypes of canine lym-
phoma is highly specific. 
In the present study no detailed analysis of the immunophenotype of neo-
plastic cells was performed. This parameter has recently been shown to have a 
significant impact on the efficacy of treatment in dogs with T-cell lymphoma. 
Avery et al. (2014) and Seelig et al. (2014) have proved that the immunoexpres-
sion of CD45 significantly correlates with the biologic behaviour of canine TCL 
lymphoma. More recently, Deravi et al. (2018) have shown that treatment out-
comes can be predicted by immunophenotype in respect of CD4, CD8, and 
MHCII immunoexpression. Unfortunately, these antibodies were not available in 
the present study, and the patients had been collected between 2009 and 2015. 
Concluding, Boxer dogs are predisposed to T-cell lymphoma, with pre-
dominance of high-grade tumour, especially pleomorphic, mixed small and large 
T-cell subtype. Neutered Boxers are roughly twice more likely to develop lym-
phoma; however, this applies only to females. There are no significant differ-
ences in clinical and laboratory parameters between low-grade and high-grade 
lymphomas. It is possible that Boxer dogs may respond less favourably to chem-
otherapy than patients of other breeds.  
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